Listed on the Australian Stock Exchange, Optiscan (OIL) is an Australian company that has developed and patented miniaturised confocal microscopes, and is now a global leader in the development and application of microscopic imaging technologies for medical markets. With the high cost of curative medicine an opportunity exists for Optiscan’s technology to be used globally to reduce costs and be used as a key tool for: > early detection of disease > use throughout stages when disease can be treated easily and effectively > providing a means to monitor responses at the cellular level so as to enable improvement to treatment outcomes
To become a global leader in microscopic imaging techniques for the medical market.
The highest level of integrity, commercially orientated innovation and technology leadership, understanding applications of our technology in medicine, personal skill development and growth, and design rigour through showing initiative, and being persistent and timely.
To create Shareholder wealth through the profitable delivery of microscopic imaging and related technologies into the global market.
Alan Hoffman has more than 20 years’ experience in executive management roles in organisations such as Shell Australia, the Wesfarmers Group and the Coventry Group.
His core strengths are improving business performance, influencing and managing change, and expertly motivating and guiding teams towards the attainment of goals.
Commercially astute and strategically focused, Alan’s leadership will drive performance improvement of Optiscan as it moves into delivering on its potential.
Dr Ian Griffiths is currently CEO of Wound Management Innovation CRC and has previously held the following positions; CEO of AorTech Biomaterials Pty Ltd, COO of AorTech International plc, CEO of PolyNovo Pty Ltd and CEO of Novoskin Pty Ltd.
Ian has worked for more than 19 years in commercialising innovative medical devices. In addition, Ian has served on a number of public and private company boards.
Dr Griffiths has an honours degree, a business degree, and a PhD from the University of Manchester with his thesis based on instrumentation physics and polymer chemistry.
Dr Griffiths has been a guest speaker at numerous public events, conferences and investment forums and has a distinguished academic publication list.
He has an extensive background in business development, licensing & acquisitions, medical technology commercialisation, capital raising and critical stakeholder management.
Ian Mann has 20 years experience as a private company director in industries including textiles, garments, investments, foodstuffs & construction materials.
One entity of which Ian is a Director became a Substantial Shareholder in Optiscan in August 2011.
Ian joined the board in December 2015 bringing financial support and vision for the path towards profitability.
Ian has been pivotal in ensuring governance and commercial focus since joining in December and remains an invaluable member of the new look board.
Peter Francis is a Partner of FAL Lawyers, a firm of commercial and technology lawyers with offices in Melbourne, Australia.
He is one of Australia’s pre-eminent lawyers on technology commercialisation and is considered to be a ‘true expert with years of experience’, ‘particularly esteemed in non-contentious circles for his dexterous handling of commercialisation work for research organisations and technology developers’ (IAM Licensing 250, 2011/2012, IAM Patent 1000, 2012).
Peter is Chairman of Benitec Biopharma Ltd (ASX:BLT) and holds a number of other non-executive director roles.
Philip Currie is a cardiologist with more than 30 years in cardiology both in the United States and in Australia with extensive experience in medical research, clinical cardiology and business. He has a medical degree, MBBS (Hons) from Monash University and an MBA from the University of Michigan. He completed his medical residency and cardiology fellowship at the Alfred Hospital in Melbourne before moving to the USA in 1983. At the Mayo Clinic, he completed a cardiology fellowship and then was a Senior Associate Cardiologist. He then was a staff cardiologist for 3 years at the Cleveland Clinic and then to Michigan as the Director of Echocardiography at the Michigan Heart and Vascular Institute for 8 years. During this time he was involved in the research/pioneering/validation of many of the major advances in echocardiography (Doppler echo, intraoperative echocardiography and transoesophageal echocardiography) including working closely as a luminary with the major international ultrasound manufacturers. In 1997, after working in the USA for 14 years, Philip returned to Australia and over the last 20 years he has successfully established a private cardiology practice which has subsequently evolved to become an integrated multispecialty medical organisation with 12 sites in Perth and Melbourne. Dr Philip Currie brings to the board a wide range of skills and broad experience including medical knowledge, medical research background, experience as the luminary interacting with international ultrasound companies, and extensive business skills based on previous MBA and a 20 year experience as the founder, owner and CEO of a large integrated medical organisation.
CHIEF EXECUTIVE OFFICER
Archie brings more than 25 years senior experience in general management, consulting and business strategy.
With strong regional and global experience across multiple industry sectors, he has held executive leadership positions at Adecco, Inchcape, Cendant and St Kilda Football Club.
CHIEF TECHNOLOGY OFFICER
Peter Delaney completed a science degree with honours in Pharmacology at Monash University in 1989. He has played a major role in the refinement of the fibre optic approach to produce a commercial instrument which received an R&D 100 Award in 1991. In 1993, Mr Delaney received the Victorian Young Achiever Award (Science and Technology) for his development of the company strategy and infrastructure. In April 2007, Peter Delaney was awarded a prestigious ATSE Clunes Ross award for excellence in the innovation and commercialisation of scientific endeavours.
Justin Mouchacca holds a Bachelor of Business majoring in Accounting. He graduated from RMIT University in 2008, became a Chartered Accountant in 2011 and since July 2013 has been the principal of chartered accounting firm, Leydin Freyer Corp Pty Ltd. The practice provides outsourced company secretarial and accounting services to public and private companies specialising in the Resources, technology, bioscience and biotechnology sectors. Justin has over 10 years’ experience in the accounting profession and has extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of Companies and shareholder relations.
Discover who is currently helping achieve the Optiscan mission.
Interested in investing in an Australian company that is making the world a healthier place?
See what we have been up to on our mission to make health easier.